Replies to post #133033 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

sentiment_stocks,

Agreed as well. What you have found coincides exactly with what what had been suggested on this board that there would be an analysis of patient response from treatment with regard to biomarker correlations and radiographic verification of mesenchymal subtype that UCLA announced had been developed. What you have found seems to indicate that FDA has indeed found that there exists a strongly statistically significant degree of correlation between DC treatment and mesenchymal genotype/phenotype and that the wording of the FDA website suggests very close ties to DCVax-L. By the way, most metastatic cancers use a pathway that is highly prone to attack by activated DC treatments. On a side note, those who are concerned about NWBO finances at this point should strongly consider how philanthropists, big pharma and other financiers eager to get their names in the limelight of a cancer treatment breakthrough might react to good news especially when PD-1 use with DCVax is controlled by an NWBO patent and NWBO could seek to license any number of potential monoclonal antibodies "like" an anti PD-1. Best wishes.